Marisa Wexler, MS,  senior science writer—

Treatment with Uptravi (selexipag) significantly improved blood flow parameters in people with inoperable or persistent chronic thromboembolic pulmonary hypertension (CTEPH) in a Phase 3 clinical trial, although its use did not significantly affect measures of physical abilities. Full trial results are in “Selexipag for the treatment of…

Among people with chronic thromboembolic pulmonary hypertension (CTEPH), risk assessments and treatment patterns prior to surgical procedures do not predict outcomes after surgery, a new study from Sweden shows. The results suggest that most CTEPH patients who don’t undergo surgery remain in the same risk category for at least…

Levels of the protein TXNRD1 are reduced in the blood of people with idiopathic pulmonary arterial hypertension (IPAH), suggesting it may be useful as a potential diagnostic marker or treatment target in IPAH, according to a new study. “This study is the first report to prove that TXNRD1 may…

The U.S. Food and Drug Administration (FDA) has approved LungFit PH, Beyond Air‘s device to administer nitric oxide therapy, to treat persistent pulmonary hypertension of the newborn (PPHN). “The FDA approval of LungFit PH enables a new era of nitric oxide therapy and marks a pivotal event for…

Treatment with an analog of sotatercept, Acceleron Pharma’s experimental therapy, eased disease-associated inflammation and changes in blood vessel architecture in multiple rodent models of pulmonary arterial hypertension (PAH), a study reported. The study, “Sotatercept analog suppresses inflammation to reverse experimental pulmonary arterial hypertension,” was published in…

Treatment with cannabidiol (CBD) reduced inflammation and lessened damaging oxidative stress in a rat model of pulmonary hypertension (PH), a new study reports. “The promising results of our research may form the basis for a more detailed study of the effects of CBD or its derivatives on PH, especially…

The U.S. Food and Drug Administration (FDA) has approved Tyvaso DPI, a dry powder, inhaled formulation of treprostinil, to improve exercise ability in people with pulmonary arterial hypertension (PAH) or pulmonary hypertension associated with interstitial lung disease (PH-ILD). Tyvaso DPI is now the only dry powder inhaler approved…

Even with modern advances in treatments, many people in the U.S. with pulmonary arterial hypertension (PAH) are at an “unacceptably high” risk of mortality, a new study shows. The study, “Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry,” was…

The European Commission is expected to propose a new governing framework for health data next month, called the European Health Data Space (EHDS), with the aim of connecting national health systems to facilitate secure and efficient transfer of data across systems in different European nations. The move is expected to…

Combining measures of symptom severity, physical function, and heart health can help predict survival outcomes in pulmonary arterial hypertension (PAH), according to a new study. The study, “Prognostic value of improvement endpoints in pulmonary arterial hypertension trials: A COMPERA analysis,” was published in The Journal of Heart and…

People with pulmonary arterial hypertension of unknown cause, or idiopathic disease, who are older, male, or of low socioeconomic status are at higher risk of death, according to a study from Korea. Researchers also found an overall survival rate of more than 50% among newly diagnosed patients. The study,…

A new company spin-out from the University of Bath, in the U.K., is developing machine learning technologies that aim to improve the accuracy of a pulmonary hypertension (PH) diagnosis by analyzing routinely acquired images of the lungs. “Using our machine learning based software we can bring the expertise of…